What’s New with PD-L1 as a Companion Diagnostic?

When:  Mar 24, 2021

Presented by Allie Cummings, B.S., HT(ASCP), Agilent Technologies

Predictive biomarker testing to inform treatment decision-making has radically influenced the practice of both pathology and oncology today. As the treatment scenario evolves, choosing the appropriate biomarker to select the right patients become vital. In this talk we will review the most up-to-date FDA approvals for checkpoint inhibitors and PD-L1 companion diagnostic assays. We will then compare the different PD-L1 scoring systems (TPS, CPS, IC, TC) and point out the role of clinical validation of PD-L1 assays. Finally, we will look at the future of cancer targeted therapies and emerging biomarkers.


This webinar is part of the 2021 Laboratory Webinar Series.
Laboratory Webinars are a great, inexpensive way to provide continuing education to a large number of employees.
The cost for each session is the same regardless of the number of attendees.

*Earn CEU's - One CEU per attendee per session
*Group Learning - Unlimited # of participants for one low fee
*Archive Sessions - Archived materials are available for 1 year to train new staff - AND STILL EARN CEUs!

NEW affordable and flexible pricing!

  • Early Bird (more than 30 days in advance) - $79.00
  • Regular (month of live event) - $99.00
  • Late (30 days after or later) - $125.00

Any questions please contact the NSH Office, 443-535-4060 or histo@nsh.org.